ArticleJAMA network open2021
Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review.BMC medicine · 2024Pooled it
- Clarifying Renal-Risk Inference From High-Sensitivity C-Reactive Protein in CKD.Kidney international reports · 2026Article
- Key considerations of explainable machine learning models for the early forecasting of acute kidney injury following cardiac surgery.International urology and nephrology · 2026Article
- The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Observational
- Dynamically predicting renal failure after development of diabetes across biobanks.PLOS digital health · 2026Article
- Real-World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- 10 tips on performing economic evaluation in kidney disease.Clinical kidney journal · 2026Review
- Clustering-derived clinical subtypes and outcomes of chronic kidney disease in patients with diabetes: a multicenter cohort study.Frontiers in endocrinology · 2026Article
- [Advanced chronic kidney disease and end-stage kidney disease in Latin America: Gaps in continuity of care, the strategic role of kidney transplantation, and challenges for health governanceDoença renal crônica avançada e terminal na América Latina: lacunas no continuum de cuidados, papel estratégico do transplante renal e desafios para a governança em saúde].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- The Association of Long COVID and CKD: Findings from the National Clinical Cohort Collaborative.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Letter by Rachana Mehta and Ranjana Sah Regarding Article, Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function.Journal of lipid and atherosclerosis · 2025Article
- Kidney Failure Risk Equation performance according to the etiology of chronic kidney disease in the CKD-CAREMEAU cohort.Clinical kidney journal · 2025Article
- Competing risk and random survival forest models for predicting survival in post-resection elderly stage I-III colorectal cancer patients.Scientific reports · 2025Article
- BRIGHT-HD-A Brazilian Research Investigation on Public Health Gains Comparing Survival Rates Between Hemodialysis and Hemodiafiltration: An Observational Study.Journal of clinical medicine · 2025Article
- Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure.Journal of the American Society of Nephrology : JASN · 2025Article
- Development of a predictive model for loss of functional and cognitive abilities in long-term care home residents: a protocol.BMJ open · 2025Article
- Review
- The Impact of Primary Renal Diagnosis on Prognosis and the Varying Predictive Power of Albuminuria in the NURTuRE-CKD Study.American journal of nephrology · 2025Article
- Fracture risk assessment in the presence of competing risk of death.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Association of life's essential 8 with chronic cardiovascular-kidney disorder: a prospective cohort study.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Kidney failure risk prediction has implications for disease management, including advance care planning in adults with severe (ie, estimated glomerular filtration rate [eGFR] category 4, [G4]) chronic kidney disease (G4-CKD). Existing prediction tools do not account for the competing risk of death. Objective: To compare predictions of kidney failure (defined as estimated glomerular filtration rate [eGFR] <10 mL/min/1.73 m2 or initiation of kidney replacement therapy) from models that do and do not account for the competing risk of death in adults with G4-CKD. Design, Setting, and Participants: This prognostic study linked population-based laboratory and administrative data (2002-2017) from 2 Canadian provinces (Alberta and Manitoba) to compare 3 kidney risk models: the standard Cox regression, cause-specific Cox regression, and Fine-Gray subdistribution hazard model. Participants were adults with incident G4-CKD (eGFR 15-29 mL/min/1.73 m2). Data analysis occurred between July and December 2020. Main Outcomes and Measures: The performance of kidney risk models at prespecified times and across categories of baseline characteristics, using calibration, reclassification, and discrimination (for competing risks). Predictive characteristics were age, sex, albuminuria, eGFR, diabetes, and cardiovascular disease. Results: The development and validation cohorts included 14 619 (7070 [48.4%] men; mean [SD] age, 74.1 [12.8] years) and 2295 (1152 [50.2] men; mean [SD] age, 71.9 [14.0] years) adults, respectively. The 3 models had comparable calibration up to 2 years from entry. Beyond 2 years, the standard Cox regression overestimated the risk of kidney failure. At 4 years, for example, risks predicted from standard Cox were 40% for people whose observed risks were less than 30%. At 2 years (risk cutoffs 10%-20%) and 5 years (risk cutoffs 15%-30%), 788 (5.4%) and 2162 (14.8%) people in the development cohort were correctly reclassified into lower- or higher-risk categories by the Fine-Gray model and incorrectly reclassified by standard Cox regression (the opposite was observed in 272 patients [1.9%] and 0 patients, respectively). In the validation cohort, 115 (5.0%) individuals and 389 (16.9%) individuals at 2 and 5 years, respectively, were correctly reclassified into lower- or higher-risk categories by the Fine-Gray model and incorrectly reclassified by the standard Cox regression; the opposite was observed in 98 (4.3%) individuals and 0 individuals, respectively. Differences in discrimination emerged at 4 to 5 years in the development cohort and at 1 to 2 years in the validation cohort (0.85 vs 0.86 and 0.78 vs 0.8, respectively). Performance differences were minimal during the entire follow-up in people at lower risk of death (ie, aged ≤65 years or without cardiovascular disease or diabetes) and greater in those with a higher risk of death. At 5 years, for example, in people aged 65 years or older, predicted risks from standard Cox were 50% where observed risks were less than 30%. Similar miscalibration was observed at 5 years in people with albuminuria greater than 30 mg/mmol, diabetes, or cardiovascular disease. Conclusions and Relevance: In this study, predictions about the risk of kidney failure were minimally affected by consideration of competing risks during the first 2 years after developing G4-CKD. However, traditional methods increasingly overestimated the risk of kidney failure with longer follow-up time, especially among older patients and those with more comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.